Paul Richardson

Apr 21, 2024 | nature.com | Natalie S. Callander |Jonathan Kaufman |Jacob P. Laubach |Timothy Schmidt |Brandi N. Reeves |Binod Dhakal | +8 more

AbstractIn the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).

Apr 9, 2024 | mdpi.com | Paul Richardson |P. G

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Sep 18, 2023 | bloomberglinea.com | Paul Richardson

ÚltimascotizacionesBloomberg — El gobierno de la República del Congo negó especulaciones en redes sociales de que había tenido lugar un golpe de Estado en el país. “Informaciones fantasiosas sugieren que puede haber graves acontecimientos en curso en Brazzaville”, dijo el portavoz del gobierno Thierry Moungalla en un comunicado publicado en Twitter, refiriéndose a la capital congoleña. “El gobierno desmiente esta noticia falsa”.

Mar 14, 2023 | nature.com | Paul Richardson |Aurore Perrot |Joseph R. Mikhael |Thomas Martin |Meral Beksac |Ivan Spicka | +2 more

AbstractThe International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab–pomalidomide–dexamethasone vs. pomalidomide–dexamethasone) and IKEMA (isatuximab–carfilzomib–dexamethasone vs.